Orfanos C E, Husak R, Wölfer U, Garbe C
Department of Dermatology, University Medical Center Steglitz, Free University of Berlin, Germany.
Recent Results Cancer Res. 1995;139:275-96.
Kaposi's sarcoma (KS) is a multicentric neoplasia of microvascular origin arising during development of immunodeficiency in human immunodeficiency virus (HIV)-infected individuals. More than 130 patients with HIV-associated KS (98% male homosexuals; median age, 35 years) have been diagnosed at the Department of Dermatology, University Medical Center Steglitz, Berlin, during the years 1982-1992. Mucocutaneous and visceral involvement was a common finding in patients with HIV-associated KS, increasing from 39% at the first visit to 65% at the last observation. In 90% of the patients significant immunosuppression was found (75% had a CD4+ count < 200/mm3) at the time of first diagnosis. However, immunosuppression was not a prerequisite for the development of KS, since the tumor had been diagnosed before severe immunosuppression was present in about 10% of the patients. Significant prognostic predictors for the final outcome were: (a) the degree of immunosuppression, (b) the presence of mucosal and visceral manifestation, and (c) the past history of opportunistic infections. The median survival time was 28 months in KS patients with more than 300 CD4+ lymphocytes (n = 18), but only 14 months in immunosuppressed (less than 300 CD4+ lymphocytes) individuals with KS (n = 70). The median survival time in the entire group evaluated (n = 89 patients) was 17 months after first diagnosis. In 71 HIV-infected individuals who died at the Berlin Department during the last 8 years, disseminated KS was the major direct or indirect cause of death (49% of cases). Therapeutic benefit for KS patients was observed after long-term administration of recombinant interferon alpha (rIFN-alpha; 9-18 million IU s.c. every 2 days) alone or combined with antiretroviral drugs such as zidovudine over several months. Prolongation of survival was found after such treatment modalities in 30%-40% of treated patients. Bleomycin and vincristine and other systemically used cytostatics have also been applied with moderate results. The etiology of HIV-associated KS is still unknown and coinfection with herpes simplex virus (HSV), cytomegalovirus (CMV), or human papillomavirus (HPV) as well as certain growth-stimulating cytokines (transforming growth factors, TGF; tumor necrosis factor alpha, TNF-alpha; interleukin-6, IL-6; tat; vascular endothelial growth factors, VEGF; oncostatin M) produced by HIV-infected cells may be cofactors. Overall, KS was found to be a tumor with high malignant potential, and the median survival times were short.(ABSTRACT TRUNCATED AT 400 WORDS)
卡波西肉瘤(KS)是一种多中心起源于微血管的肿瘤,发生于人类免疫缺陷病毒(HIV)感染个体免疫缺陷发展过程中。1982年至1992年间,柏林施泰格利茨大学医学中心皮肤科诊断出130多名与HIV相关的KS患者(98%为男性同性恋者;中位年龄35岁)。皮肤黏膜和内脏受累在与HIV相关的KS患者中很常见,从首次就诊时的39%增加到最后一次观察时的65%。90%的患者在首次诊断时发现有明显的免疫抑制(75%的患者CD4 + 细胞计数<200/mm³)。然而,免疫抑制并非KS发生的先决条件,因为约10%的患者在出现严重免疫抑制之前就已诊断出肿瘤。最终结局的重要预后预测因素为:(a)免疫抑制程度,(b)黏膜和内脏表现的存在情况,(c)机会性感染病史。CD4 + 淋巴细胞超过300个的KS患者(n = 18)的中位生存时间为28个月,但免疫抑制(CD4 + 淋巴细胞少于300个)的KS患者(n = 70)的中位生存时间仅为14个月。整个评估组(n = 89例患者)首次诊断后的中位生存时间为17个月。在过去8年中于柏林科室死亡的71例HIV感染个体中,播散性KS是主要的直接或间接死亡原因(49%的病例)。单独长期给予重组干扰素α(rIFN-α;每2天皮下注射900 - 1800万国际单位)或与齐多夫定等抗逆转录病毒药物联合使用数月后,观察到对KS患者有治疗益处。经此类治疗方式后,30% - 40%的治疗患者生存时间延长。博来霉素、长春新碱和其他全身使用的细胞抑制剂也已应用,效果一般。与HIV相关的KS的病因仍不清楚,单纯疱疹病毒(HSV)、巨细胞病毒(CMV)或人乳头瘤病毒(HPV)的合并感染以及HIV感染细胞产生的某些生长刺激细胞因子(转化生长因子,TGF;肿瘤坏死因子α,TNF-α;白细胞介素-6,IL-6;反式激活因子;血管内皮生长因子,VEGF;制瘤素M)可能是辅助因素。总体而言,KS被发现是一种具有高恶性潜能的肿瘤,中位生存时间较短。(摘要截选至400字)